Abstract
The rise of multi-drug resistant and extensively drug resistant M. tuberculosis around the world poses a great threat to human health, and necessitates development of new, effective and inexpensive anti-tubercular agents. The availability of knowledge on molecular biology of M. tuberculosis infection coupled with whole genome sequences, transcriptomic, proteomic and metabolomic data sets have provided insights on the genes/proteins indispensable for initiation and maintenance of persistence, cross-talk with and/or sensing the host immune response, and finally the reactivation of persistent M. tuberculosis to a growing state. The review will focus on analysis of current state of M. tuberculosis genomic resources, host-pathogen interaction studies in the context of pathogen persistence, and the efforts made or required in the development and utilization of computational tools, models and metabolic network analyses to speed up the process of drug target discovery, particularly eradicating the dormant infections.
Keywords: M. tuberculosis, drug, targets, resistance, persistence, dormancy, genomics, computational, protein-network.
Current Pharmaceutical Design
Title:Can Mycobacterial Genomics Generate Novel Targets as Speed-Breakers Against the Race for Drug Resistance
Volume: 20 Issue: 27
Author(s): R.S. Chauhan, S.K. Chanumolu, Chittaranjan Rout and Rahul Shrivastava
Affiliation:
Keywords: M. tuberculosis, drug, targets, resistance, persistence, dormancy, genomics, computational, protein-network.
Abstract: The rise of multi-drug resistant and extensively drug resistant M. tuberculosis around the world poses a great threat to human health, and necessitates development of new, effective and inexpensive anti-tubercular agents. The availability of knowledge on molecular biology of M. tuberculosis infection coupled with whole genome sequences, transcriptomic, proteomic and metabolomic data sets have provided insights on the genes/proteins indispensable for initiation and maintenance of persistence, cross-talk with and/or sensing the host immune response, and finally the reactivation of persistent M. tuberculosis to a growing state. The review will focus on analysis of current state of M. tuberculosis genomic resources, host-pathogen interaction studies in the context of pathogen persistence, and the efforts made or required in the development and utilization of computational tools, models and metabolic network analyses to speed up the process of drug target discovery, particularly eradicating the dormant infections.
Export Options
About this article
Cite this article as:
Chauhan R.S., Chanumolu S.K., Rout Chittaranjan and Shrivastava Rahul, Can Mycobacterial Genomics Generate Novel Targets as Speed-Breakers Against the Race for Drug Resistance, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118165427
DOI https://dx.doi.org/10.2174/1381612819666131118165427 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Anti-tubercular Activity of 6-(<i>4</i>-Chloro/Methyl-phenyl)-4- Arylidene-4,5-dihydropyridazin-3(2<i>H</i>)-one Derivatives Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Tachykinins and Neuropsychiatric Disorders
Current Drug Targets A Computational Molecular Docking Studies on the Tryparedoxin Peroxidase of <i>Leishmania donovani</i> Responsible for Visceral Leishmaniasis in Human
Letters in Drug Design & Discovery Biologic Agents for Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Meet Our Editorial Board Member
Infectious Disorders - Drug Targets Isoniazid Induced Convulsions at Therapeutic Dose in an Alcoholic and Smoker Patient
Current Drug Safety Expression, Purification, Crystallization and Preliminary X-Ray Crystallographic Analysis of the Resuscitation Promoting Factor Interacting Protein RipA from M. tuberculosis
Protein & Peptide Letters Synthesis and SAR of Some New 4 Substituted 3H-1,2,3,5-oxathiadiazole 2-Oxides as Antifungal Agents
Letters in Drug Design & Discovery Hepatitis C Viruss Immune Evasion Strategies
Current Immunology Reviews (Discontinued) Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent
Current Drug Discovery Technologies Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening “Self-Antigenic Universe” and Tuberculosis Vaccine Development
Current Pharmacogenomics and Personalized Medicine Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Veterinary Vaccines from Transgenic Plants: Highlights of Two Decades of Research and a Promising Example
Current Pharmaceutical Design Synthesis, Antimycobacterial Activities and Phototoxic Evaluation of 5H-thiazolo[3,2-a]quinoline-4-carboxylic Acid Derivatives
Medicinal Chemistry Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Infective Drug Discovery Editorial (Thematic Issue: Drug Delivery Australia)
Current Drug Delivery QSAR Studies on NTF1836 Analogues as Mycothiol Biosynthesis Inhibitors
Letters in Drug Design & Discovery